The Food and Drug Administration (FDA) is concealing pharmaceutical companies’ violations of the law that have made members of the public “guinea pigs,” a health insurance watchdog group said yesterday.
Good Manufacturing Practice (GMP) inspections conducted by the FDA earlier this year of pharmaceutical manufacturers found that many drugs had been manufactured in a way that failed to comply with what had been described in their marketing authorizations, Democratic Progressive Party Legislator Chen Chieh-ju (陳節如) said.
The inconsistencies are in violation of the Pharmaceutical Affairs Act (藥事法), the Pharmaceutical Good Manufacturing Practice Regulations (藥物優良製造準則) and the Regulations for Registration of Medicinal Products (藥品查驗登記審查準則), and the firms and the FDA have placed patients at risk due to inadequate safety and quality of the drugs produced, Chen said in a joint statement issued with the National Health Insurance Civilian Surveillance Alliance.
The alleged changes, without seeking the approval of the regulator, have been made to package inserts, packaging and the excipient used, the group said.
However, the most dangerous of the violations has been the failure to provide bioequivalence (BE) test reports, or reports on clinical trials and whether, by monitoring the differences in blood levels, a potential to-be-marketed generic drug product is bioequivalent to a reference brand-name pharmaceutical, it added.
“As of this March, the FDA found at least 3,841 items that failed to comply with the regulations. We have no idea how many of these drugs did not have BE reports, since a request to the FDA for the relevant information has been denied by the authority, which cited the Personal Information Protection Act,” Huang Sue-ying (黃淑英), convener of the alliance, told a press conference at the legislature in Taipei.
The FDA has not asked firms producing these substandard products to suspend manufacturing nor have the products been withdrawn from the market. The list of products and the relevant information has not been made public, which means patients and healthcare providers cannot avoid using these drugs, she added.
What has enraged the group is how the drug companies’ actions were exposed. The FDA made an announcement on March 28 saying that for drugs without a BE report, but which have been on the market for at least five years and thereby have a long-term clinical experience, “their clinical experience can substitute for the required BE test if no serious adverse effects or therapeutic inequivalence have been reported.”
“This is no different to exploiting patients, allowing them to become the manufacturers’ guinea pigs at the NHI’s expense,” alliance spokeswoman Eva Teng (滕西華) said.
What is more, drugs that were manufactured and marketed after Jan. 1, 2009, and which therefore do not meet the five-year requirement, have been granted a two-year probationary period to complete BE tests without a suspension of sales of the drug during the testing period, Huang said.
“The BE test reports done by the these manufacturers are only subject to random spot-checks by the FDA,” Huang said.
In response, FDA official Tzou Meir-chyun (鄒玫君), who was also present at the press conference, said all pharmaceutical products currently on the market have been approved by the FDA, with BE tests conducteds before being approved.
“They are all post-approval changes. As post-approval changes can be, according to international standards, categorized into major and minor changes, it is only when major changes take place that a further risk assessment is needed,” Tzou said.
The FDA released a statement later in the day saying that a risk assessment meeting evaluating the drugs that underwent major changes — about 5 percent of the drugs where post-approval changes have been made — would be held within the next month.
Three batches of banana sauce imported from the Philippines were intercepted at the border after they were found to contain the banned industrial dye Orange G, the Food and Drug Administration (FDA) said yesterday. From today through Sept. 2 next year, all seasoning sauces from the Philippines are to be subject to the FDA’s strictest border inspection, meaning 100 percent testing for illegal dyes before entry is allowed, it said in a statement. Orange G is an industrial coloring agent that is not permitted for food use in Taiwan or internationally, said Cheng Wei-chih (鄭維智), head of the FDA’s Northern Center for
LOOKING NORTH: The base would enhance the military’s awareness of activities in the Bashi Channel, which China Coast Guard ships have been frequenting, an expert said The Philippine Navy on Thursday last week inaugurated a forward operating base in the country’s northern most province of Batanes, which at 185km from Taiwan would be strategically important in a military conflict in the Taiwan Strait. The Philippine Daily Inquirer quoted Northern Luzon Command Commander Lieutenant General Fernyl Buca as saying that the base in Mahatao would bolster the country’s northern defenses and response capabilities. The base is also a response to the “irregular presence this month of armed” of China Coast Guard vessels frequenting the Bashi Channel in the Luzon Strait just south of Taiwan, the paper reported, citing a
UNDER PRESSURE: The report cited numerous events that have happened this year to show increased coercion from China, such as military drills and legal threats The Chinese Communist Party (CCP) aims to reinforce its “one China” principle and the idea that Taiwan belongs to the People’s Republic of China by hosting celebratory events this year for the 80th anniversary of the end of World War II, the “retrocession” of Taiwan and the establishment of the UN, the Mainland Affairs Council (MAC) said in its latest report to the Legislative Yuan. Taking advantage of the significant anniversaries, Chinese officials are attempting to assert China’s sovereignty over Taiwan through interviews with international news media and cross-strait exchange events, the report said. Beijing intends to reinforce its “one China” principle
A total lunar eclipse, an astronomical event often referred to as a “blood moon,” would be visible to sky watchers in Taiwan starting just before midnight on Sunday night, the Taipei Astronomical Museum said. The phenomenon is also called “blood moon” due to the reddish-orange hue it takes on as the Earth passes directly between the sun and the moon, completely blocking direct sunlight from reaching the lunar surface. The only light is refracted by the Earth’s atmosphere, and its red wavelengths are bent toward the moon, illuminating it in a dramatic crimson light. Describing the event as the most important astronomical phenomenon
RSS